David A. Siegel Olema Pharmaceuticals, Inc. Transaction History
Two Sigma Advisers, LP
- $47 Billion
- Q3 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Olema Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 21,100 shares of OLMA stock, worth $183,359. This represents 0.0% of its overall portfolio holdings.
Number of Shares
21,100
Previous 144,400
85.39%
Holding current value
$183,359
Previous $615,000
66.99%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding OLMA
# of Institutions
135Shares Held
65.9MCall Options Held
379KPut Options Held
13K-
Bain Capital Life Sciences Investors, LLC Boston, MA6.84MShares$59.5 Million21.2% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY6.79MShares$59 Million2.11% of portfolio
-
Bvf Inc San Francisco, CA5.3MShares$46 Million2.76% of portfolio
-
Black Rock Inc. New York, NY4MShares$34.8 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X03.59MShares$31.2 Million0.02% of portfolio
About Olema Pharmaceuticals, Inc.
- Ticker OLMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,419,600
- Market Cap $351M
- Description
- Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, local...